Jefferies Financial Group Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its target price dropped by stock analysts at Jefferies Financial Group from $32.00 to $28.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 152.71% from the company’s current price.

KURA has been the topic of a number of other research reports. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday. HC Wainwright lifted their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $29.43.

Kura Oncology Stock Performance

Shares of KURA opened at $11.08 on Thursday. The stock has a 50-day moving average of $18.28 and a two-hundred day moving average of $19.82. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $861.58 million, a P/E ratio of -4.95 and a beta of 0.86. Kura Oncology has a one year low of $9.06 and a one year high of $24.17.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC boosted its position in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after acquiring an additional 583,155 shares during the last quarter. Vanguard Group Inc. lifted its stake in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares during the last quarter. Armistice Capital LLC grew its position in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares in the last quarter. Finally, Artal Group S.A. grew its position in shares of Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock valued at $40,951,000 after purchasing an additional 151,828 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.